1. Home
  2. IFRX vs SHIM Comparison

IFRX vs SHIM Comparison

Compare IFRX & SHIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IFRX
  • SHIM
  • Stock Information
  • Founded
  • IFRX 2007
  • SHIM 1990
  • Country
  • IFRX Germany
  • SHIM United States
  • Employees
  • IFRX N/A
  • SHIM N/A
  • Industry
  • IFRX Biotechnology: Pharmaceutical Preparations
  • SHIM
  • Sector
  • IFRX Health Care
  • SHIM
  • Exchange
  • IFRX Nasdaq
  • SHIM Nasdaq
  • Market Cap
  • IFRX 65.8M
  • SHIM 57.8M
  • IPO Year
  • IFRX 2017
  • SHIM 2023
  • Fundamental
  • Price
  • IFRX $1.69
  • SHIM $1.68
  • Analyst Decision
  • IFRX Strong Buy
  • SHIM Hold
  • Analyst Count
  • IFRX 4
  • SHIM 2
  • Target Price
  • IFRX $8.50
  • SHIM $3.00
  • AVG Volume (30 Days)
  • IFRX 262.5K
  • SHIM 19.5K
  • Earning Date
  • IFRX 05-07-2025
  • SHIM 05-14-2025
  • Dividend Yield
  • IFRX N/A
  • SHIM N/A
  • EPS Growth
  • IFRX N/A
  • SHIM N/A
  • EPS
  • IFRX N/A
  • SHIM N/A
  • Revenue
  • IFRX $140,242.00
  • SHIM $482,303,000.00
  • Revenue This Year
  • IFRX $61.96
  • SHIM N/A
  • Revenue Next Year
  • IFRX $80.59
  • SHIM $8.37
  • P/E Ratio
  • IFRX N/A
  • SHIM N/A
  • Revenue Growth
  • IFRX 30.90
  • SHIM N/A
  • 52 Week Low
  • IFRX $0.82
  • SHIM $1.30
  • 52 Week High
  • IFRX $2.82
  • SHIM $4.94
  • Technical
  • Relative Strength Index (RSI)
  • IFRX 62.40
  • SHIM 53.23
  • Support Level
  • IFRX $1.53
  • SHIM $1.30
  • Resistance Level
  • IFRX $1.92
  • SHIM $1.99
  • Average True Range (ATR)
  • IFRX 0.19
  • SHIM 0.17
  • MACD
  • IFRX 0.02
  • SHIM 0.02
  • Stochastic Oscillator
  • IFRX 74.59
  • SHIM 54.81

About IFRX InflaRx N.V.

InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

About SHIM Shimmick Corporation

Shimmick Corp is a leading provider of water and other critical infrastructure solutions nationwide. It selectively focuses on the following types of infrastructure projects: Water Treatment, Water Resources, and Other Critical Infrastructure. In water treatment projects the company expands, rehabilitates, upgrades, builds and rebuilds water and wastewater treatment infrastructure, including desalination plants. In water resources projects company builds, expands, and improves water storage and conveyance, dams, levees, flood control systems, pump stations, and coastal protection. In Other Critical Infrastructure projects, It builds, retrofits, expands, rehabilitates, operates, and maintains its nation's critical infrastructure, including mass transit, bridges, and military infrastructure.

Share on Social Networks: